Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Nasdaq5d
NextCure, Inc. Doses First Patient in Phase 1 Study of B7-H4-Targeting Antibody-Drug Conjugate LNCB74
through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in ...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development strategy in the rigorous and cutting-edge field of novel drug therapeutics at ...
PharmiWeb2d
Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose ...
Korea Joongang Daily on MSN11h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
BioNTech SE: BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a next-genera ...
Le Lézard2d
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...
Armed robbery in Revesby4d
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Frontiers2d
Bispecific Antibodies and their Conjugates in Solid Tumors and Hematological Malignancies
Bispecific antibodies (BsAbs) are a major advancement in therapeutic oncology and hematology, capable of simultaneously engaging two distinct targets. This ...